AvevoRx, a national, independent provider of specialty infusion pharmacy services, has announced it will provide Alpha-1 proteinase inhibitor drugs to patients with Alpha-1 antitrypsin deficiency as part of a nationwide clinical offering. This marks AvevoRx’s official entry into the Alpha-1 market, which is limited to a very small panel of specialized, home infusion pharmacy providers. Alpha-1 is the latest specialized infusion therapy offered by AvevoRx, whose primary specialties include immune globulin (IG) and monoclonal antibody treatments and acute infusion therapies such as IV antibiotics and total parenteral nutrition.
“We are delighted to join the Alpha1 community,” said Ric Logsdon, AvevoRx program manager for Alpha-1. “The company’s unique and robust management experience – over 150 years combined in Alpha-1 – positions us well to compete for the privilege of caring for this patient community.”
Also Read: New Meijer Grocery Stores Open Doors to Fresh, Convenient Retail Experience…
“We have an amazingly strong bench of Alpha-1 experience at every level of the organization, including pharmacy, nursing, customer service, consumer advocacy, billing, and finance,” commented Justin Dent, PharmD and AvevoRx’s national director of pharmacy operations. “AvevoRx brings the knowledge and infrastructure to provide services and programs typically expected of much bigger pharmacies while leveraging our adaptability and commitment to delivering an extraordinarily customized, personal patient experience.”
This class of drugs is intravenous biologicals derived from human plasma called Alpha-1 proteinase inhibitors. Each is used to treat a rare form of congenital emphysema, often caused by a patient’s Alpha-1 antitrypsin deficiency. The drugs are administered intravenously as often as every week, typically in the patient’s home or AvevoRx’s ambulatory infusion suites. Of the four drugs in this class currently approved for use in the U.S., AvevoRx will be dispensing and administering three of them.
Alpha-1 antitrypsin deficiency is a genetic disorder that could cause lung and liver disease in affected patients. The age at which the first signs and symptoms of the deficiency appear often varies, though resulting lung disease frequently develops between ages 25 and 50. Those affected often develop emphysema, a lung disease caused by damage to the air sacs in the lungs (alveoli). Roughly 10 percent of infants with an Alpha-1 antitrypsin deficiency will develop liver disease resulting in yellowing of the skin and eyes (jaundice); Approximately 15 percent of adults with the deficiency will develop liver damage (cirrhosis) due to the formation of scar tissue in the liver.
Testing for Alpha-1 antitrypsin deficiency is encouraged for those at high risk of inheriting this disorder, according to the Alpha-1 Foundation. Testing is available through a physician or can be conducted anonymously (Alpha-1 Foundation, 2022).
SOURCE: PRWeb